HP
ALNY icon

Havemeyer Place’s Alnylam Pharmaceuticals ALNY Stock Holding History

Havemeyer Place’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.83M Buy
9,415
+6,537
+227% +$1.97M 0.28% 120
2026
Q1 		$952K Buy
2,878
+2,580
+866% +$878K 0.11% 318
2025
Q4 		$119K Buy
+298
New +$132K 0.02% 461

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Havemeyer Place's ALNY Position: Q2 2026 in Review

Havemeyer Place increased its Alnylam Pharmaceuticals (ALNY) stake by 227% in Q2 2026, buying an estimated $1.97M and bringing the position to 9,415 shares worth $2.83M. The position accounts for 0.28% of the portfolio, ranked #120.

Havemeyer Place first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Havemeyer Place held 9,415 shares of Alnylam Pharmaceuticals worth $2.83M as of Q2 2026.
  • Havemeyer Place bought 6,537 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.97M.
  • Alnylam Pharmaceuticals made up 0.28% of Havemeyer Place's portfolio in Q2 2026, its #120 holding.
  • Havemeyer Place first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Havemeyer Place's 13F filing for Q2 2026, filed 13 Aug 2026.